Evidence map›Paper›PMID 29961822›Full record

ReviewThe international journal of neuropsychopharmacology2019

The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review.

Koen Demyttenaere, Zeno Van Duppen

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The international journal of neuropsychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 49 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04701866 nacompletednot on this mapstarted 2021, after this paper: background citation

Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study

TypeinterventionalSponsorDouglas Mental Health University InstituteRan2021 to 2022Enrolled32ConditionsDepressive Disorder, Treatment-Resistant, Depressive Disorder, Major, Unipolar Depression, Depression, BipolarArmsMusic
NCT05833087 narecruitingnot on this mapstarted 2023, after this paper: background citation

A Randomized Controlled Trial of Schema Therapy for Patients With Chronic Treatment Resistant Depression

TypeinterventionalSponsorRegion of Southern DenmarkRan2023 to 2029Enrolled129ConditionsTreatment Resistant Depression, Chronic DepressionArmsSchema therapy, Other psychotherapy, Standard care package content
NCT06303739 phase3active not recruitingnot on this mapstarted 2024, after this paper: background citation

Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2024 to 2027Enrolled20ConditionsRefractory Depression, Treatment Resistant DepressionArmspsilocybin
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Definition of treatment-resistant late-life depression: Conclusions from a European Task Force Delphi process.European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Article
  13. Article
  14. Article
  15. Rethinking the Treatment-Resistant Depression.Advances in experimental medicine and biology · 2026
    Review
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Koen DemyttenaereUniversity Psychiatric Center KU Leuven and KU Leuven, Faculty of Medicine, Department of Neurosciences, Research Group Psychiatry.
Zeno Van DuppenUniversity Psychiatric Center KU Leuven, Campus Kortenberg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment-resistant depression refers to major depressive disorder, treatment of the disorder, and failure to obtain an "acceptable" outcome. Regarding the disorder, the heterogeneous concept of major depressive disorder and the multiple definitions of treatment-resistant depression, hesitating between a categorical and a more dimensional approach, as well as the divergence between diagnostic criteria and the items in the assessment scales are a source of confusion. Classifications do not take into account the dramatic influence of patient characteristics strongly impacting outcome, although these can be the cause of so-called pseudo-resistance. Outcome is the result of spontaneous evolution, nonspecific factors (including placebo), and active treatment factors. These should be differentiated to have a reliable estimation of the impact of different treatment modalities before we can asses treatment-resistant depression or before we can ascertain the (non)efficacy of treatments for treatment-resistant depression.The impact and burden of major depressive disorder and treatment-resistant depression are immense and go far beyond their economic cost. It is often forgotten that both are not only associated with increased suicidality but also with nonsuicidal mortality and that both can even result in requests for assisted dying. The caregiver burden and associated stigma are also too often overlooked despite that it has been suggested that they do influence (treatment) outcome.

Indexed as

Cost of IllnessDepressive Disorder, Treatment-ResistantMajor Depressive DisorderHumans

Identifiers

PMID29961822
PMCPMC6368367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.